These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28002067)

  • 21. Accelerating HIV vaccine development.
    Koff WC
    Nature; 2010 Mar; 464(7286):161-2. PubMed ID: 20220821
    [No Abstract]   [Full Text] [Related]  

  • 22. HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.
    Kwong PD; Mascola JR
    Immunity; 2018 May; 48(5):855-871. PubMed ID: 29768174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV vaccine development--improving on natural immunity.
    Johnston MI; Fauci AS
    N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447
    [No Abstract]   [Full Text] [Related]  

  • 24. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
    O'Connell RJ; Kim JH; Excler JL
    Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cure of HIV infection: is the long wait over?
    Shearer WT
    J Allergy Clin Immunol; 2014 Jul; 134(1):20-2. PubMed ID: 25117800
    [No Abstract]   [Full Text] [Related]  

  • 26. New center focuses on neutralizing antibodies.
    McEnery R
    IAVI Rep; 2008; 12(5):15. PubMed ID: 20210066
    [No Abstract]   [Full Text] [Related]  

  • 27. Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question.
    Hope TJ
    Nat Med; 2011 Oct; 17(10):1195-7. PubMed ID: 21988997
    [No Abstract]   [Full Text] [Related]  

  • 28. HIV. The modern era of HIV-1 vaccine development.
    Mascola JR
    Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931
    [No Abstract]   [Full Text] [Related]  

  • 29. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model.
    Dzhivhuho GA; Rehrl SA; Ndlovu H; Horsnell WGC; Brombacher F; Williamson AL; Chege GK
    PLoS Pathog; 2018 Jul; 14(7):e1007182. PubMed ID: 30048550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural infection as a blueprint for rational HIV vaccine design.
    van Haaren MM; van den Kerkhof TL; van Gils MJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):229-236. PubMed ID: 27649455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus.
    Schell JB; Bahl K; Folta-Stogniew E; Rose N; Buonocore L; Marx PA; Gambhira R; Rose JK
    Virology; 2015 Feb; 476():405-412. PubMed ID: 25591175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cape Town connections.
    Dumiak M
    IAVI Rep; 2014; 18(4):4-10. PubMed ID: 25625172
    [No Abstract]   [Full Text] [Related]  

  • 34. Antibody gene transfer for HIV immunoprophylaxis.
    Balazs AB; West AP
    Nat Immunol; 2013 Jan; 14(1):1-5. PubMed ID: 23238748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approaches to the induction of HIV broadly neutralizing antibodies.
    Moore PL; Williamson C
    Curr Opin HIV AIDS; 2016 Nov; 11(6):569-575. PubMed ID: 27559709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infectious disease: Beating the big three.
    Bourzac K
    Nature; 2014 Mar; 507(7490):S4-7. PubMed ID: 24611168
    [No Abstract]   [Full Text] [Related]  

  • 37. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel approaches in preclinical HIV vaccine research.
    Safrit JT; Koff WC
    Curr Opin HIV AIDS; 2016 Nov; 11(6):601-606. PubMed ID: 27636502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference.
    Ross AL; Bråve A; Scarlatti G; Manrique A; Buonaguro L
    Lancet Infect Dis; 2010 May; 10(5):305-16. PubMed ID: 20417413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.